StockNews.com started coverage on shares of Cellectis (NASDAQ:CLLS – Free Report) in a research note issued to investors on Friday morning. The brokerage issued a hold rating on the biotechnology company’s stock. Several other brokerages have also recently commented on CLLS. JMP Securities reissued a market outperform rating and set a $6.00 price target on […]